{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:10:05Z","timestamp":1791943805524,"version":"4.3.4"},"reference-count":18,"publisher":"Society of Nuclear Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.2967\/jnumed.122.264402","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T20:45:13Z","timestamp":1663879513000},"page":"402-409","source":"Crossref","is-referenced-by-count":37,"title":["<sup>177<\/sup>Lu-PSMA-I&amp;T for Treatment of Metastatic Castration-Resistant Prostate Cancer: Prognostic Value of Scintigraphic and Clinical Biomarkers"],"prefix":"10.2967","volume":"64","author":[{"given":"Amir","family":"Karimzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Heck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Tauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Knorr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Haller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calogero","family":"D\u2019Alessandria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang A.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Rauscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2022,9,22]]},"reference":[{"key":"2023033021451401000_64.3.402.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30198-0"},{"key":"2023033021451401000_64.3.402.2","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2018.11.016","article-title":"Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer","volume":"75","author":"Heck","year":"2019","journal-title":"Eur Urol."},{"key":"2023033021451401000_64.3.402.3","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.183194"},{"key":"2023033021451401000_64.3.402.4","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet."},{"key":"2023033021451401000_64.3.402.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2023033021451401000_64.3.402.6","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00259-020-04797-9","article-title":"Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617: a WARMTH multicenter study (the 617 trial)","volume":"48","author":"Ahmadzadehfar","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023033021451401000_64.3.402.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.158550"},{"key":"2023033021451401000_64.3.402.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.231431"},{"key":"2023033021451401000_64.3.402.9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"2023033021451401000_64.3.402.10","doi-asserted-by":"publisher","DOI":"10.2307\/2529310"},{"key":"2023033021451401000_64.3.402.11","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2021.03.004","article-title":"A systematic review and meta-analysis of the effectiveness and toxicities of lutetium-177-labeled prostate-specific membrane antigen-targeted radioligand therapy in metastatic castration-resistant prostate cancer","volume":"80","author":"Sadaghiani","year":"2021","journal-title":"Eur Urol."},{"key":"2023033021451401000_64.3.402.12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s00259-017-3848-4","article-title":"PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and\/or enzalutamide: a retrospective analysis of overall survival","volume":"45","author":"Rahbar","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023033021451401000_64.3.402.13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/pros.23912","article-title":"The value of tumor markers in men with metastatic prostate cancer undergoing [177Lu]Lu-PSMA therapy","volume":"80","author":"Yordanova","year":"2020","journal-title":"Prostate."},{"key":"2023033021451401000_64.3.402.14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.216820"},{"key":"2023033021451401000_64.3.402.15","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/s41585-019-0251-x","article-title":"Radium-223 mechanism of action: implications for use in treatment combinations","volume":"16","author":"Morris","year":"2019","journal-title":"Nat Rev Urol."},{"key":"2023033021451401000_64.3.402.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.241588"},{"key":"2023033021451401000_64.3.402.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263441"},{"key":"2023033021451401000_64.3.402.18","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1007\/s00259-021-05237-y","article-title":"Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review","volume":"48","author":"Manafi-Farid","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.122.264402","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T04:47:25Z","timestamp":1680238045000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.122.264402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,22]]},"references-count":18,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,2]]},"published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.2967\/jnumed.122.264402"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.122.264402","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,22]]}}}